Excellent result of FluoGuide’s FG001 guiding surgical removal of cancer is published

FluoGuide A/S’s ("FluoGuide") compound FG001 lights up the cancer and its invasive growth and has demonstrated potential to vastly improve the radicality of surgery in preclinical studies. FluoGuide can announce that data which confirms FG001’s potential in guiding surgical removal of pancreatic cancer has now also been published in peer reviewed journal.

The study aimed at investigating the resection of the human pancreatic cancer using an orthotopic xenograft pancreatic cancer model and also to investigate if fluorescent-guided imaging could locate additional metastases after conventional removal of metastasis under traditional surgical white light. As previously communicated, this preclinical study was conducted similarly to the way human cancer patients are treated. 

The result demonstrated that FG001 helped to identify and remove local additional metastases in 50% of the subjects that were overlooked during the standard white light procedure. The study was conducted with the aim of evaluating the potential clinical benefit of FG001 to completely remove local cancer during surgery using human cancer, performed by a surgeon who operates on humans and using standard surgical equipment.

The data underlined the vast potential of uPAR target products in guiding surgical removal of cancer beyond glioblastoma which has the primary focus of FluoGuide. Pancreatic cancer remains one of the deadliest cancers and the 5-year survival rate is very low, making the need for improved treatment extensive.

The article is titled “Improved surgical resection of metastatic pancreatic cancer using uPAR targeted in vivo fluorescent guidance: comparison with traditional white surgery”. FluoGuide’s Chief Scientific Officer Andreas Kjær is one of the co-writers of the research paper (link to article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824874/).

Additional material:
The link (https://youtu.be/6AgQiTsozXQ) shows a movie of the removal of the cancer, where cancer is left behind without use of FG001.


For further information, please contact:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com

__________________________________________________________________________________

About FluoGuide 
FluoGuide A/S (Spotlight Stock Market: FLUO:SS) provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s first product FG001 increases precision in cancer surgery by lighting up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to reduce suffering for the patients and increase the likelihood of cure. It can also reduce costs for the health care system for the benefit of society. FluoGuide focuses on demonstrating the effect of FG001 in patients by conducting a human proof-of-concept clinical trial and expects to announce the first result of this study during first half of 2020.

About FG001
FG001, FluoGuide’s first product, lights up the cancer and its invasive growth into the surrounding tissue. It helps the surgeon remove the entire tumor during surgery and increases the chance for complete cure of the patient. The task for the surgeon is simply to "turn the lights on and see the entire tumor". The solution helps surgeons remove a minimal amount of normal tissue while also reducing the risk of leaving cancer tissue behind. This reduces the suffering of the patient and increases the likelihood of cure, and also reduces costs for the health care system. FG001 is currently prepared for a proof-of-concept clinical study.

About Us

FluoGuide A/S develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue. Preclinical studies have demonstrated the potential of FG001 to vastly improve the likelihood of performing radical surgery (removal of all cancer) and thereby improving outcome and survival. FluoGuide is initially focused on glioblastoma (brain tumor) but the Company plan to expand its business to other solid tumors. Market launch of FG001 in a first country is expected in 2022/2023.

Subscribe

Quotes

We are now producing the FG001 in a quality for use in patients. We have everything in place and the surgeons are ready to begin testing the new technology. That way, they can become even better at what they are doing already - removing cancer and thus hopefully healing patients.
Andreas Kjær, CSO